The Cooper Companies, Inc. $COO Shares Acquired by Waverly Advisors LLC

Waverly Advisors LLC increased its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 1,180.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,360 shares of the medical device company’s stock after purchasing an additional 53,802 shares during the period. Waverly Advisors LLC’s holdings in Cooper Companies were worth $4,185,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Avalon Trust Co acquired a new position in shares of Cooper Companies during the second quarter worth about $25,000. Root Financial Partners LLC grew its stake in shares of Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares in the last quarter. SJS Investment Consulting Inc. raised its holdings in shares of Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after buying an additional 187 shares during the period. Elevation Wealth Partners LLC raised its holdings in shares of Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after buying an additional 375 shares during the period. Finally, Continuum Advisory LLC acquired a new position in Cooper Companies during the 2nd quarter worth approximately $30,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Stock Performance

Cooper Companies stock opened at $53.91 on Friday. The Cooper Companies, Inc. has a 52 week low of $51.01 and a 52 week high of $89.83. The company has a current ratio of 1.22, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. The stock has a market cap of $10.51 billion, a P/E ratio of 18.40, a price-to-earnings-growth ratio of 1.45 and a beta of 0.82. The stock has a 50 day moving average of $71.62 and a 200-day moving average of $69.70.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, analysts expect that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its board has initiated a share repurchase plan on Wednesday, September 9th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on COO. Mizuho set a $75.00 price target on Cooper Companies and gave the stock an “outperform” rating in a report on Thursday. William Blair cut shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Cooper Companies in a report on Friday, September 4th. Stifel Nicolaus set a $70.00 price target on shares of Cooper Companies and gave the stock a “buy” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. cut their price objective on shares of Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a report on Thursday. Five research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $71.47.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.